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The Treatment of G-onorrhoea by Uleron, Albucid, 
and M. & B. 695.
So recently as 1934 the writer of a textbook on 
Venereal Diseases was able to say, ”It can be taken as an 
axiom that no drug cures Gonorrhoea1’. A little more 
than two years later the integrity of that axiom was 
challenged when the work of Domagk on Prontosil was 
made public. Since that time the derivatives of 
Sulphanilamide have followed each other on to the 
market with bewildering rapidity, and the attendant 
literature is rich in well authenticated claims of 
success ( and in some cases, failure ). So changed, 
in fact, is the position, that what was unpleasant 
dogmatism in 1934 would be dogmatic ignorance in 1940.
For the purposes of the clinical investigation 
recorded herein, three closely related drugs were 
employed, Uleron, Albucid, and M.& B. 693. Buttle (1939) 
described these compounds as ’’drugs of the second class 
of sulphanilamide derivatives, where substituents are 
introduced into the amide group”. In this they differ 
from the earlier sulphanilamide derivatives, such as 
prontosil rubrum and proseptasine, wherein substituents 
were added to the amino group. It was claimed for the 
’’second group” of derivatives not only that they possessed 
a lower toxicity, but that the.y retained their identity 
as active agents in the body, and did not depend for 
their action on the liberation of sulphanilamide. For 
more detailed observations the three drugs must be 
reviewed individually.
ULERON.
This preparation, which has the structural 
formula :-
>  S 0 , N H <  >S0„N(CHP,
and is described chemically as 4 - (4f-amino-benzol- 
sulphonamide)-benzol-sulphon~dimethylamide, is a 
colourless substance, soluble with difficulty in water,
and is put up in 0.5 gramme tablets.
First reported on by G-riitz (1937), who used it and 
allied preparations in a group of thirty-six patients, it 
was later the subject of investigation by Felke (1937),
Fisher (1937) and many others. During 1938 approximately 
160 articles appeared describing the results of using 
the preparation in gonorrhoea, most of them by 
Continental authorities. It will be sufficient to notice 
a few of the more important of these articles in order 
to estimate the general quality of results achieved 
on the Continent.
Mergelsberg (1938 a), using a maximum of three 
’’Stosses11 (short courses of treatment) separated by 
suitable intervals, and not exceeding a total of 12 
grammes per three days, found that old gonorrhoea 
responded best, and that results were quite good in 
complications. His figures are interesting: sixty-nine 
cases of old gonorrhoea which had preliminary 
irrigations gave a 77 per cent. cure. W. and K.
G-ennerich (1938), using similar dosage and a preliminary 
two to three weeks1 irrigation with J to 1 per cent.albargin, 
treated sixty-four cases (fifty-eight of them male), all 
of whom finally passed tests of cure. Fifty-six of these 
responded to 1, six to 2, and two to 3 ’’Stosses”.
Fuhs and Volavsek (1938 a), using a seven-day ’’Stoss”
(the makers of the drug consider this inadvisable because 
of the risk of toxic effects) obtained 90 per cent, cure in 
133 men, a n d -97.3 per cent, in thirty-six women. In 
later publications Mergelsberg (1938 b) showed improvement 
on his original figures. He recorded 87.5 per cent, cure 
in a group of patients irrigated with ^ to f per cent, 
protargol solution four times daily whenever the first 
’’Stoss” had failed. Later Fuhs and Volavsek (1938 b), 
still using their seven-day ’’Stoss”, claimed 90 per cent, 
cure in 299 men and 94 per cent, in 80 women. Their
total experience of the drug amounted to 486 cases.
British literature on uleron is less copious, 
o ’Hanlon (1938) recommended its use in cases not 
cured by sulphanilamide. Walsh (1938), in a preliminary 
article, described its effects on forty-three cases of male 
gonorrhoea. His judgement was favourable although his 
case records were rendered inconclusive by the under­
treatment of at least fifteen patients. At such an early 
stage in the use of the drug his caution was easily to be 
understood. Cokkinis and McElligott (1938a) quoted 
their experiences in 150 cases and note that the product has 
no immediate toxic effects. They regard its ultimate 
curative value, however, as ’’much lower than that of 
sulphanilamide”. Hanschell (1938a), on the other hand, 
referred to 200 cases treated with uleron, and believed it 
not only to be safer, but more effective for male 
gonorrhoea than sulphanilamide. Harrison (1938) 
dealt with the mode of application. He recommended 
that the administration of uleron should be delayed until 
at least three weeks after the onset of the attack.
Polyneuritis and uleron.
Special reference must be made to 
accounts of polyneuritis attributed to the action of this 
drug. It seems probable that the preference shown in this 
country for sulphanilamide and M. & B. 693 may be 
traced to the effect of these reports.
A leading article in the Lancet (August 13, 1938) 
expresses the opinion that there is no doubt of the 
striking efficiency of uleron as an anti-gonococcal 
agent, but adds ”it differs from all other such compounds 
in causing a polyneuritis, the commonest manifestation 
of which is a palsy affecting the peroneal and other 
leg muscles”. The authorities quoted for this latter 
statement are Freusberg (1938) and Burger (1938). Hanschell 
(1938b) does not appear to have encountered polyneuritis
in 212 male cases over a period of' seven months. Cokkinis 
and McElligott (1938b) seemed doubtful of the value of 
Hanschell’s evidence on the ground that his patients were 
of the sea-going type, and could not be adequately observed 
for relapse or delayed complications, Valkenburg and 
Borne (1938) reported at length an apparent Uleron 
polyneuritis. The patient was a man of 63 and the 
condition developed after 16 grammes of the drug had 
been taken (for a non-gonococcal infection). Evidence of 
a diet deficient in Vitamin B-^  and subsequent response 
to the administration of Betabion Forte led Valkenburg 
and Borne to conclude that the predisposition in this 
patient might have been a Vitamin B^ deficiency. A later 
report from Hanschell (1939) reported neuritis in a 
seaman 28 years old. This was a case of self-medication 
after default. Two hundred tablets (100 grammes) were 
taken at the rate of six a day. Hanschell stated that 
this was the first neuritis he had seen in 270 cases 
treated with uleron. Hanschell’s statement is the more 
interesting when we remember that his patients are 
seafaring and, one imagines, more likely than most people 
to reveal Vitamin Bj deficiency.
ALBUCID.
Albucid, the second of the group of drugs under 
test, has a formula
and is described as p.aminobenzenesulphonacetamide. Its 
production was the result of efforts to discover a form 
of sulphanilamide derivative of unusually low toxicity 
combined with maximum therapeutic effectiveness. Albucid 
is a white powder, weakly acid, and is prepared in 0.5 
gramme tablets for oral administration. It is soluble 
in Hydrochloric acid and in a alkalis, and is readily 
absorbed by the stomach and small intestine.
The use of the drug in this country appears to have
> S0„NH-C0CH
been restricted and there is little reference to it in 
British literature. Considerable work, on the other 
hand, has been undertaken in America, but the chief 
source of information is Germany, and especially 
the original investigations of Vonkennel and Korth (1938). 
They found that a concentration of 1:20,000 would destroy 
gonococci in vitro, and that a maximum concentration
after
of 5 mg % was obtained in the blood A  a single peroral 
dose of 5.0 grammes of Albucid. Clinical investigation 
then:seemed feasible, but they preferred first to test 
the toxicity of the drug by self administration. When 
their own tolerence was demonstrated they treated 
patients with seven-day courses, giving an individual 
dosage of as much as 52.5 grammes during the course.
Their observations on the practical use of Albucid 
were based on the treatment of 103 cases of gonorrhoea 
(71 male and 32 female). Of the male cases 18 were 
anterior and 53 posterior infections. They achieved 
a cure rate of 80.3 per cent, in the male cases and
89.7 in the female. 14 male cases and 3 female cases 
failed to respond. Pre-vaccination and local lavage 
with 1:4,000 potassium permanganate solution were 
also applied in these cases.
Later they treated 25 acute male infections, 
employing immediate therapy with no adjuvant treatment 
or preparation. Six of these failed to respond. They 
obtained their best results when using lavage and 
prevaccination.
In unsuccessful male cases they frequently found 
a resistant focus in the prostate, gland infiltrations, 
or a para-urethral tract. No allergic or toxic reactions 
in the urine, blood, internal organs, or nervous system 
were observed, and no azoospermia was encountered. In 
two instances a transient exanthema was seen. Tests of 
cure were thorough.
Later Korth treated 200 cases of male gonorrhoea, 
adhering to the technique which had "been developed.
86.5 % were discharged cured after one course, and 
altogether 93 % of cures was recorded after a second 
course had been given. The average duration of treatment 
was 25 days for one course, and for two courses 45 days..
No secondary effects were observed.
It has been mentioned that comparatively little 
attention has been paid to Albucid in this country. Buttle 
(1939) mentioned its use and, relying on personally 
communicated reports, spoke of good results obtained 
when the drug was employed with the usual adjuvant 
treatment.
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M & B 693._____
The third drug with which we are concerned is 
M & B 693. This may be described as
2-(p-aminobenzenesulphonamido)-pyridine. The structural 
formula is
It is a white pov/der of slightly bitter taste 
and soluble in water to the extent of about 1:1000.
The drug is put up in o.5 gm tablets.
The literature which has grown around M & B 693 
is formidable in extent, but most of it is concerned 
with the actions of the drug upon non-gonococcal 
infections. The history of its use in the chemotherapy 
of gonorrhoea is less difficult to trace. As early as 
June 1938, Lloyd, Srskine, and Johnson published a 
preliminary report in the Lancet. Their verdict was 
inconclusive, but hopeful. Cokkinis and McElligott 
(1938a) referred to the use of M & B 693, but had 
insufficient data to draw definite conclusions.
Prebble (1938) wrote of its relatively low toxicity. He 
found toxic reactions less frequently than when 
sulphanilamide was used, but more frequently than was 
usual with Uleron. He recommended a dosage of six 
tablets daily for five days.
The bacteriostatic effect of the drug was 
investigated by Maegraith and Vollum (1938) and compared 
with those of sulphonamide-p, and soluseptasine. In the 
presence of leucocytes the action of M & B 693 on 
gonococci was. superior except at very low concentrations. 
In "deleucocyted” blood, however, soluseptasine was found 
to be much more effective.
McGregor Robertson (1938) reported on the use of 
M & B 693 in some 300 cases of acute gonorrhoea. About
100 cases were treated at each of three Glasgow clinics 
and the respective results were very similar. The drug 
appeared somewhat less successful where no irrigation was 
performed. At Black Street Glinic no failures were 
encountered in 100 cases treated, although tests of cure 
and subsequent observation were not carried far enough 
to guarantee ultimate cure. The dosage employed was three 
grammes daily for five days and two grammes for a further 
two days (19 grammes). Treatment was started as soon as 
possible, (The disease was of less than four days duration 
in 63 % of the cases) in view of conclusions drawn from 
previous experience with sulphanilamide. In daily 
urethral smears the gonococci often disappeared, or were 
extracellular after 24 hours. About 45 % of the patients 
complained of toxic effects (headache, nausea, dizziness, 
dyspnoea). A rash was seen on four occasions.
Marinkovitch (1939) treated fifty male patients 
with a total of 42 grammes (4 tablets daily for 21 days). 
Daily lavage with potassium permanganate was given over 
the same period. This treatment produced a permanent cure 
rate of 86 % in the cases he investigated. Toxic effects 
were negligible and no complications occurred. 12 % of 
his cases relapsed before tests of cure 'were completed.
Dr,D.Kathleen Brown (1939) reported on the use of the 
drug in 27 cases of gonococcal vulvovaginitis. The 
patients were children and it is doubtful whether her 
findings are strictly relevant to the present 
investigation. It will suffice to note that the results 
were good.
McIntosh and Whitby (1939) investigated the action 
of M & B 693. It is interesting to note (in view of the 
opinion of Maegraith & Vollum 1938 to the contrary) that 
they wrote, " leucocytes are not necessary to the action 
of the drug”. They advanced the view that " the
-9-
admini strati on of sulphonamicle drugs has no stimulating 
action on the hody defences11. Nor, apparently do they 
affect the speed of production or the !fquantity and 
quality of specific immune bodies11. Whilst, these 
investigators found M & B 693 active in highly virulent 
organisms, neither in vivo or in vitro was the action 
immediate. They concluded that the effect of the drug 
was not merely germicidal, but probably operated by 
neutralization of some metabolic function or enzymotic 
activity, in effect impeding the nourishment of the 
bacteria and thus inhibiting growth. This assumption,if 
well-founded, has important bearing upon the problem of 
relapse after sulphonamide treatment.
Hallam (1939) reported a case of severe ultra­
violet burning in a patient who was taking M & B 693. The 
exposure itself was too moderate to account for the 
severity of the skin and general reactions, but the 
evidence was too slender to warrant the assumption that 
the predisposition was photosensitization due to M & B 693. 
Six grammes of the drug had been taken o^er a period 
of four days.
Bowie, Anderson, Dawson, and Mackay (1939) treated 
127 cases of gonorrhoea in the male. The majority were 
acute infections and uncomplicated. Like McGregor 
Robertson (op.cit.) Bowie and his colleagues deprecate 
delayed drug therapy. Of 97 patients who completed the 
course (various dosages were tried) and attended for tests 
of cure, 91 (93 per cent.) were apparently cured. Toxic 
reactions were not severe and varied directly with dosage. 
Renbom (1939) treated and cured a case of gonococcal 
proctitis with M & B 693. Sommerville (1939) treated 
152 cases of gonorrhoea in the male, of which practically 
all were acute. Thirteen cases defaulted and five did not 
respond to the drug. Early cure was obtained in 90 % of 
those cases which attended regularly. Eleven cases relapsed
-10-
and their relapse was attributed to alcohol. The apparent 
failures responded quickly to irrigation. One interesting 
conclusion reached by Sorrimerville is that a moderate dosage 
(one tablet four times a day) is shown by his figures to 
be productive of the best results. He encountered no 
complications and although toxic reactions were observed 
in 39 per cent, of the cases, these were never severe.
Abse (1939) cited instances of failure in the use of the 
drug. He provided no data, but instanced cases where the 
disease had remained latent after apparently successful 
treatment. Browdy (1939) uttered a similar warning, but 
provided no clinical evidence to substantiate his point of 
view. Both these reports seem to be based on the incontestible 
fact that some general practitioners have applied M & B 693 
indiscriminately to gonococcal infections, have allov^ed 
self-medication without due supervision and have omitted 
to insist upon thorough tests of cure. The moral is evident. 
Forgan, however, thought fit to underline it and pleaded 
for more thorough tests of cure and a closer liaison 
between general practitioners on the one hand, and medical 
officers and venereologists on the other.
Thompson (1939) described rashes (simulating measles, 
rubella, and scarlet fever) resulting from the administration 
of M & B 693. He mentioned three cases, none of which 
were gonococcal infections.
Buttle (1939) writing of the pharmacology of the 
sulphanilamide group, mentioned the potency of M & B 6 j3 
in gonococcal infections. He found that it was absorbed 
and excreted more slowly in animals than sulphanilamide, 
and reached the cerebrospinal fluid more slowly. He 
observed that drugs of this group 1fdo not work very well 
where there is a considerable tissue breakdown due to 
suppuration - as in streptococcal or gonococcal cases with 
abscesses1’. The drugs are not a substitute for local 
surgical procedures. Discussing toxic symptoms, Buttle 
made occasional reference to Ivi & B 693. He found that it
produced depression more markedly than did sulphanilamide. 
Of all toxic reactions he judged agranulocytosis to he 
the most serious condition produced by these drugs and 
he referred to six cases attributed to the action of 
M & B 693. He insists that all patients who receive drugs 
of the sulphanilamide group for more than 10 days should 
have a blood count every third day. The most troublesome 
symptoms with which M & B 693 was associated were nausea 
and vomiting.
Cokkinis and McElligott (1939) published a study 
of late relapses after sulphonamide cure of gonorrhoea. 
They analysed 1,268 male and 210 female cases, whose 
chemotherapy was completed from six months to two years 
previously and who had passed all tests of cure. In the 
male cases the late relapse rate was 30%. Patients 
treated with M & B 693 and Uleron seemed more liable 
to relapse than those treated with sulphanilamide. The 
comparative figures for the three drugs were M & B 693
18.5 per cent; Uleron 18 per cent; sulphanilamide 7.8 
per cent. In the female cases Uleron was not used, but 
the relapse rate with sulphanilamide was considerably 
higher than with M & B 693. (The M & B 693 cases were 
only followed up for eight months at the most, whilst 
the sulphanilamide cases were two years old.) It 
should be mentioned that in the estimation of early 
relapses (male) the positions were reversed and 
M & B 693 showed only 8.6 per cent against sulphanilamide
17.7 per cent. Cokkinis and McElligott do not attach 
much significance to these comparative figures. They 
do assert, however, that delayed therapy decreases 
the incidence of both early and late relapse. Where 
chemotherapy was delayed for a week after the onset of 
the disease, vaccine-therapy was also given and this 
may account, in some measure, for the lower incidence 
of relapses in that group. Very few of the relapses
- 12-
above mentioned could be traced to inadequate dosage.
Perhaps the most signal fact emerging from this report is the 
failure of the exhaustive tests of cure to reveal the still 
present, hut evidently dormant gonococci. Cokkinis add 
McElligott go so far as to say that "negative tests are 
not proofs of cure in cases treated by chemotherapy.!l
Commenting on the above report, Mascall (1939) 
reported an increase in relapses at Whitechapel after 
sulphonamide "cure" of gonorrhoea; he also noticed an 
increase in the so-called gonococcal carrier since the 
advent of sulphonamide treatment. Assinder and Knight
(1939) criticised the rather haphazard competition of 
percentages in the article by Cokkinis and McElligott 
(1939 op.cit.). They prefer M & B 693 to Uleron and 
sulphanilamide and find only 13% relapses in over a 
thousand cases (male and female) treated with M & B 693.
Many of these cases were under observation for over a 
year. With reference to delayed treatment, Gardner (1939) 
asked whether the figures analysed by Cokkinis and 
McElligott referred only to randomly selected cases in 
which treatment was withheld until the second week, or 
whether they included cases which did not report before 
that time. He suggests that the late-comers may be 
patients whose infections are relatively mild, or in whom 
the progress of the disease is retarded by a stronger natural 
resistance or they may be careless people who neglect 
to come for treatment and may be equally careless 
about reporting relapse. These factors would all tend to 
show a decreased relapse rate for the second-week cases. 
Stuart (1939), quoting experience at Portsmouth (but 
without data) thought Cokkinis and McElligott over­
estimated the probability of relapse. He recommended 10 
grains of sodium bicarbonate to be given with each gramme
of M & B 693 to increase absorption and so make a 
smaller dose more effective. Sandes (1939) stressed 
the importance of the complement-fixation test being 
carried out in a laboratory, where the technique of the 
test is in regular use.
Throughout this correspondence there were references 
to an increase in the number of defaulters after 
sulphonamide chemotherapy.
Taylor (1940) reported on 100 male cases treated 
with M & B 693 delayed therapy,3 gm daily for 14 days. 
Lavage with mercury oxycyanide and potassium permanganate 
(alternate weeks) was given. If a prostatic massage three 
Y\reeks after commencement of treatment produced a bead 
negative for pus and gonococci, it was followed by 
irrigation with silver nitrate. 64per cent of cases passed 
all tests of cure and an additional 33 per cent were 
apparently cured. Analysis of a further 150 cases (no 
data given) showed similar results. Taylor encountered 
three rashes and other slight toxic reactions. Prebble
(1940) reported on 305 male cases, 160 of them acute.
He used a dosage of 3 gm daily for one week followed by
1.5 gm daily for a further week. Irrigations with 1 in 8000 
oxycyanide of mercury were employed in almost all cases. 
Complications were rare and toxic reactions were observed 
in less than 6% of patients treated.
Pringle, Dockeray and Mitchell (1940) reported" a 
severe case of agranulocytosis following treatment with 
M & B 693 (46.5 gm over a period of 18^ - days) in the 
absence of one other apparent toxic reaction. The patient 
was being treated for pneumonia.
Clinical Material.
A carefully controlled clinical investigation 
of the three drugs Uleron, Albucid, and M & B 693 
was undertaken at the Venereal Diseases Department 
of the Leicester Royal Infirmary. The number of 
cases treated was in some instances more than twice 
the number reported on herein. For the purpose of the 
investigation,however, it was considered that only 
those cases should be included which by reason of 
strictly regular attendance could be regarded as 
valid for statistical analysis. All male cases were 
acute gonococcal infections. Moreover, all the cases 
mentioned hereafter were supervised personally by the 
writer during treatment and subsequently during tests 
of cure. The number which fulfilled these conditions 
were as follows:
Standard of cure.
No patient was dismissed as cured until the 
routine tests of cure had been passed. For male 
patients these tests consisted of three prostatic 
smears (the patient not having urinated for three 
hours, and the glans penis cleaned thoroughly with 
surgical spirit), the passing of a metal sound into 
the bladder, urethroscopic examination, and a 
provocative gonococcal vaccine test. A complement 
fixation test was not done in all cases.. These tests 
cover a period of some six weeks and a good interval 
was allowed between ,Tapparent cure" and the tests of 
cure. It should be pointed out that a few cases 
defaulted before tests could be completed, and
Uleron 
Albucid 
M & B 693
50 (female)do
these have only been included where observation was 
carried far enough for a reasonable conclusion to be 
reached. They fall mainly under the heading "probably 
cured", and their default is in each case indicated in 
the tables.
For female patients the tests of cure consisted 
of a post-menstrual cervical and urethral smear after 
three consecutive periods. The first of these tests; was 
preceded by a provocative vaccine. A culture examination 
was resorted to in all doubtful cases.
TREATMENT WITH ULERON. (lOO male cases of acute
gonococcal infection.)
(See Table No.1.)
We come now to the details of treatment with the 
first of the three drugs. Uleron was given to a 100 
male cases of recent gonococcal infection. All v/ere 
found to have gonococci in direct urethral smears on 
the first attendance at the clinic and on the day 
immediately before the commencement of Uleron treatment. 
They were all clinically and pathologically acute 
gonococcal urethritis on the first attendance at the 
clinic. Seven had complications at the outset of 
treatment. These complications were peri-urethral 
abscess (one), epididymitis (two), copaiba rash (one), 
toxic conjunctivitis (one), retention of urine (One). 
Later, but before the first Uleron course, a further 
twelve developed complications as follows: epididymitis 
(five), peri-urethral abscess (two), cystitis (two), 
prostatitis with rheumatism (one), slight rheumatism 
(one), and arthritis of knees and ankles (one).
Adjuvant Treatment. Daily irrigations were given 
(posterior from the outset where possible) with
-16-
1 in 10,000 potassium permanganate solution. The use 
of the urethral syringe was not advised. Gonococcal 
vaccines were not administered.
ULERON - Mode of administration.__
The drug was administrated in short three-day 
courses (or Stosses) separated hy varying short intervals 
(usually nine days). It will have "been noticed in the 
survey of ULERON literature that the "Stoss" technique 
has heen used fairly generally with ULERON in order 
to lessen the incidence of possible secondary effects.
The following printed instructions were given.
1st day:- Two tablets three times after food.
2nd & 3rd days:- Two tablets four times a day
after food.
A full glass of water to be taken after each
two tablets, and no eggs or salts (Glauber or
Epsom) to be taken during the three days.
It is of interest to note that occasional 
patients have admitted neglect of the above pre­
cautions; one patient, for instance, took a daily 
quantity of "Epsom" salts during the treatment, but 
suffered notdiscomfort. Nevertheless, the precaution has 
been observed when administering any of the sulphanilamide 
derivatives.
It will be seen that the total dosage during one 
Stoss was twenty-two tablets (eleven grammes).
Delayed therapy was the rule in treatment with 
Uleron. Much has already been said about the 
advisability of allowing a short period for the 
development of maximum resistance; in this series of 
cases the average duration of urethral discharge before 
beginning Uleron treatment was ,17.9 days. The average 
interval between the first and second Stosses was 9.2 
days, and that between the second and third Stosses
10.8 days.
Twenty-eight cases received only one Stoss,forty-two 
received two Stosses, and thirty received three.
Fig.l. CLINICAL PICTURE OP 100 CASES ON COMPLETION 
OP ULERON TREATMENT.
Clinical picture 
immediately following 
course(s).
Clinical picture 
after period of 
observation.
No sign 
of in­
fection.
Less
dis­
charge.
No
change.
Re­
lapse.
Appar­
ent
cure
Appar­
ent
failure.
28 cases
receiving
ONE
course
only.
18 9 1 1 26 1
42 cases
receiving
TWO
c ours e s 
only.
31 9 2 4 35 3
30 cases
receiving
THREE
courses
only.
15 2 13 4 13 13
Total of 
100 cases 
receiving 
ONE, P/VO, 
or THREE 
courses.
64 20 16 9 74 17
Figure I shows the clinical picture of 100 cases on 
completion of the Uleron treatment, and Figures II,
III and IV the clinical or pathological picture 
immediately after one, two, or three Uleron Stosses, 
Complete and detailed protocols of all cases treated 
with Uleron are to he found hereafter (p. 3£\. ).
It is intended in Fig.l to show as clearly as 
possible the effect of Uleron treatment in cases which 
have been grouped according to the number of Stosses 
administered. Figure II gives, so to speak, a. 
cross-section of the results of treatment immediately 
after the first course of Uleron. It therefore includes 
the total material of a 100 cases.
Fig.II - Clinical and Pathological Picture of 
100 Cases immediately following One 
Uleron Course (including those who 
later received Further Uleron 
Treatment).
No Sign of 
Infection
Less Discharge No Change
G.C.- G. G.
100 cases 48 24 14 14
It was not considered necessary to give further 
treatment to twenty-seven of the above cases after 
observing them for a few days. Another case defaulted 
while still infected, and is recorded (see Fig.l) as 
an "apparent failure".
Seventy-two patients received a second course. 
This number includes 16 who relapsed after dis­
appearance of discharge on the first course, 
fourteen who remained free of discharge but whom it 
was thought advisable to treat further, twenty-six 
who showed "less discharge" but did not relapse, 
and thirteen who failed to respond to the course.
Pig.Ill - Clinical and Pathological Picture of
Seventy-two Cases immediately following Two 
Uleron Courses,
No Sign of 
Infection
Less Discharge No Change
Gr. C. — G.C.+
72 cases, 40 12 6 14
It was not considered necessary to give further treatment 
to thirty-eight (although four of these subsequently 
relapsed). Three were recorded as napparent Uleron failures’* 
after two courses.
Thirty patients received a third course. This number 
includes six who relapsed after disappearance of discharge 
following two courses, three who remained free from dis­
charge but whom it was thought advisable to treat further, 
ten who showed less discharge after two courses, and 
eleven who failed to respond to two courses. That only 
eleven of the fourteen cases showing no improvement in 
the previous table were given a third course seems to call 
for explanation. The three cases which were not treated 
further are accounted for as follows; (l) Case 68 failed 
completely to respond and was given other treatment;
(2) Case 95 was given other treatment; (3) Case 100 
developed urticaria after the second course,! and further 
use of the drug was thought inadvisable.
Pig,IV. - Clinical and Pathological Picture of Thirty 
Cases immediately following Three Uleron 
Courses.
No Sign of 
Infection
Less Discharge No Change
G.C.- G.C.+
30 cases 15 2 0 13
Only 50 per cent, of the 30 cases treated v/ith a 
third course shov/ a distinctly favourable result (Fig. IV), 
This, ofcourse, is to he expected, for the group comprises
-20-
thos0 cases which respond siovi/ly to Uleron and. those 
which do not respond at all.
CONTROL GASES.
For the purpose of comparison 100 consecutive 
cured acute cases were taken from a previous year. All 
had received daily irrigations and had eventually 
completed routine tests of cure. The average duration 
of discharge was fifteen weeks. Complications (mild and 
severe) occurred in 24 % of these cases.
DISCUSSION & CONCLUSIONS.
The analysis of one hundred cases leaves little 
doubt about the value of Uleron as a chemotherapeutic 
agent for acute gonorrhoea. It' will have been noticed 
that delayed therapy was employed, and that irrigations 
were given in all cases. A number of acute cases were 
put on uleron at first attendance, but eventually this 
practice was discontinued, the results being less 
satisfactory. In the cases reviewed here the average 
duration of discharge before the commencement of Uleron
treatment was nearly three weeks (17.9 days).
irrigation.
As far as adjuvant treatment is concerned, irrigation 
seems to justify itself. This impression was strengthened 
by a preliminary investigation of the use of Uleron 
without any irrigation.
770.C.
Particular attention has been given to the importance 
of a long observation period between ^apparent cure” 
and application of the routine T.O.C. The T.O.C. must 
be even more scrupulously carried out for cases treated 
by chemotherapy than for cases treated by the older 
methods.
ftesuLTs.
  The results obtained in this series, while they
testify to the worth uf Uleron in the treatment of 
gonorrhoea, vary a little from the experience which 
is reflected in Uleron literature generally. In the 
first place they do not confirm the almost unqualified
approval of German workers; in the second place, they 
do not confirm the forbodings of many British writers 
concerning toxicity. It may be that regulated dosage 
and very careful supervision during treatment has 
induced a mode of treatment which by its moderation 
fails to attain the maximum cure rate but lessens the 
incidence of toxic complications.
After one Uleron course 26 per cent, showed an 
"apparent cure” and were subsequently proved to be 
definitely "cured”. After two courses a further 35 per 
cent, gave a similar result, thus bringing the total 
up to 61 per cent. After three courses another 13 per 
ceht, was added to the "apparent cures” (followed by 
successful T.O.C.), the total now reaching 74 per cent. 
Nine per cent, of the cases treated relapsed after a 
temporary clearing up of the symptoms. Seventeen per 
cent, were definitely unresponsive to treatment and 
must be classed as Uleron failures. It will be seen 
that these figures are somewhat lessjimpressive than 
those obtained in the Continental clinics, where only 
about 10 per cent, of failures was admitted.
Toxic reactions at Leicester, however, were 
slight. Three patients complained of slight headache, 
four of a slight nausea, and two developed a severe 
generalysed urticaria (one after the second course and 
one after the third). The urticaria cleared up rapidly 
when the drug was stopped. Neither polyneuritis nor 
acute aneamia occured during this series. Since 
polyneuritis has been particularly associated with 
the use of Uleron, it is of interest to note that the 
majority of the patients at the Leicester clinic are 
city workers and remain active, for the most part, 
during treatment. Of their diet little can be said 
with certainty except that they are probably better 
nourished than most British workpeople. The bulk of
f the patients were labourers, engineers, or factory
operatives. The peak age for new infections is between 
25 and 35.
Shifts’- There is every reason to believe that the relapse
rate of 9 per cent, is final for this series; no others 
have been reported. One of the ’’relapses” appeared 
clinically free from gonorrhoea for a period of seven 
weeks before relapsing. It is extremely improbable that 
this case was re-exposed to infection.
’ONOCOCCnL
“^ Compuc^ no^ s. G-onococcal complications before and after treatment
totalled 19 per cent, (in the controlled cases this total
was 24 per cent.). The average duration of discharge
(including the period before attending the clinic) for
the ’’apparent Uleron cures” was thirty-five days, in
contrast to fifteen weeks in the controlled cases, 
f'f/c- i n f e c tio tv,
Uleron does not appear to hinder re-infection.
Two cases in the first group were re-exposed and the 
disease was just as acute as before. Both had been 
definitely cured and had past all T.0.0.
The relatively low toxicity of Uleron as used in 
this series should not be interpreted as sanction for 
its indiscriminate use. Experience has shown that where 
Uleron is administered under inadequate medical super­
vision, or without medical advice at all, it can be 
extremely dangerous.
TREATMENT WITH ALBUCID. ( 50 male cases of acute
gonococcal infection). See Table
CLIN< CFU?_
HIQTERtm..
Fifty acute gonococcal infections in male patients were 
treated with Albucid. All revealed gonococci in direct 
urethral smears at their first attendances and on the 
day immediately preceding the commencement of 
chemotherapeutic treatment. They were all clinically 
and pathologically acute gonococcal urethritis when 
they presented themselves at the clinic.
Co/yiPi/c^ r/orvs.
There were seven gonococcal complications in this 
group, relatively more than in that treated with 
Uleron (7 %-}.
Before Albucid was administered the following 
conditions were noticed painful left inguinal gland 
(one), rheumatism (two), acute epididymitis (four).
The same general policy was followed with regard 
to adjuvant treatment, all patients being subjected to
! lavage with 1 in 10,000 pot.permang.soln. Again no
I
gonococcal vaccines were used.
since the precautions of ’’Stoss” treatment were 
not necessary in the case of Albucid, a course of 42 
tablets in seven days (two tablets three times a day) 
was given. Each patient therefore had 21 grammes. For 
this series of cases more prompt chemotherapy was tried. 
The patients reported at the clinic within an average 
time of 4.4 days after the first appearance of the 
discharge. The average period allowed to elapse between 
the onset of the disease and the commencement of Albucid 
treatment was 9.1 days (as against 17.9 days in the
Uleron series).
Results
Of the fifty cases, thirty passed all tests of 
cure and did not relapse. Ten cases showed an improved 
clinical picture on completion of treatment, but 
relapsed quickly. Ten cases altogether failed to 
respond. It was decided to continue treatment in the 
case of one of the latter category, so that it might be
seen if the complete failure to respond, was due to 
insufficient or insufficiently protracted dosage. 
Accordingly case A25 was given a second and then a third 
course of 22 grammes. There was still no response. A 
few such stubborn infections were later treated with 
Uleron or M & B 693. Altogether, of the 10 which failed 
to respond to Albucid, two were cured by M & B 693 and 
two by Uleron. Of those which relapsed after Albucid 
two were cured by the agency of M & B 693. Two more 
Albucid failures were treated with M & B 693 but without 
success (cases A 46 & A 47).
Thus only 60 % of cures resulted from the use of 
Albucid, the figure being increased to 72 % by the aid 
of other chemotherapeutic agents, notably M & B 693.
Toxicity.
~ ~ Toxic reactions were confined to one severe
generalised urticaria, and three instances of nausea.
QQNCLU^tONS,
Albucid was found to be a drug of remarkably 
low toxicity. In this respect it is the most remarkable 
of all the sulphanilamide derivatives. It is more 
difficult, however, to be convinced of its high 
therapeutic value. Of 50 typical acute gonococcal 
infections only 60 % were cured. When several cases 
were selected for re-treatment with Albucid or other 
drugs, the figure was raised to 72 % (due to the 
action of M & B 693 and Uleron). It is possible 
that a longer delay before treatment would have tended 
to produce better results. Against this, however, it 
should be noticed that the Albucid failures were cases 
which had a discharge for an average of 8.9 days before 
treatment. The normal period for the series was 9.1.
This does not suggest that Albucid failures were more 
rare when a longer delay was instituted before treatment.
TREATMENT WITH M & B 695 >. (100 cases of acute
gonococcal infection 
in the male).
See Table No.III.
CLlNICfiL.
MftTERinL. _ , _
One hundred acute gonococcal infections in male 
patients were treated with M & B 693. All revealed 
gonococci in direct urethral smears at their first 
attendances and on the day immediately preceding 
the commencement of chemotherapy. All were clinically 
and pathologically acute gonococcal urethritis when
they presented themselves at the clinic.
Co m  r u  c a t i o n s
Thirteen patients had gonococcal complications 
before treatment. There were four instances of 
epididymitis, two of infected peri-urethral follicle, 
two of Tyson1s abscess, one of prostatitis, one of 
arthritis, two instances of concurrent rheumatism 
and prostatitis, one of dorsal lymphangitis, and one 
of cystitis. For the purpose of comparison it is 
well to remember that against this "complication 
rate” of 14 % the Uleron group had 7 % and the 
Albucid group also 14 %. Three patients of the 
M & B 693 group developed further complications 
during treatment as follows : one epididymitis(after 
30 gms)f one cystitis and one arthritis of the right 
knee with toxic conjunctivitis. It will be remembered 
that in the Uleron group 12 patients developed later 
complications.
7*E/jT,Y}£:rYT: In this series it was decided to put to the test
the general principle heretofore established that from 
the outset posterior irrigation should be used 
where ever possible. Consequently fifty of the cases 
(cases 1 to 50) were given the drug without concurrent 
irrigation and fifty (cases 51 to 100) were irrigated 
as before with 1 in 10,000 pot. permang. solution. No 
gonococcal vaccines were used.
-26-
TecuNtooe of
#D/VWVtsriZiqT(Oty
The normal course was 60 tablets (30 gms) and the 
dosage six tablets daily (two tablets three times a 
day). The problem of immediate or delayed therapy was 
complicated in this series by the inclusion of a few 
patients who did not present themselves at the clinic 
until many weeks after the onset of the disease. The 
problem is further complicated by the inclusion of a 
number of long-standing infections which had failed to 
respond to other methods of treatment. All these cases 
were still clinically and pathologically acute or sub­
acute gonococcal urethritis. However, for the whole 
series the average duration of tne discharge before 
attendance at the clinic was 5.7 days ( the exclusion 
of 4 late-attending cases would lower this average 
to 3.9 days). The average duration of discharge before 
commencing treatment with M &. B 693 was 22.2 days 
(if we disregard 13 previously treated cases referred 
to above, this average is drastically reduced to 6.3 days. 
It may be said generally that chemotherapy in this series 
was fairly prompt except where M & B 693 v/as applied 
to infections which had withstood other methods or 
in those cases where.first attendance at the clinic 
was delayed by the patient concerned. It is generally 
safe to say that wherever possible M & B 693 was 
commenced about a week after the onset of the disease0 
During treatment frequent clinical and 
pathological examinations were undertaken with a 
view to the presentation of a continuous picture of 
the effects of the treatment. It is not possible to 
discuss individual case-records here, but the progress 
of individual patients under treatment can easily be 
followed from the protocols (Table III).
' The broad results of treatment with M & B 693 may
now be set out. Sixty-six patients were able to pass
- 27-
all teats of cure and were discharged from the clinic. In 
addition, seventeen cases defaulted either late in 
treatment or during tests of cure. In these cases 
treatment and observation had been carried far enough 
to warrant their classification as "probable cures”. It 
is quite often the case that the unwilling attender 
loses his enthusiasm for treatment when his condition 
ceases to be a source of worry or discomfort. If these 
"probable cures” are added to the "certain" cures, 
a cure rate of 83 % is reached. Relapses after 
treatment numbered 9 (9%), and 8 (8%) of the patients 
failed to respond to M & B 693.
Q e n e r r l ,
2>tSCUSStON
In this series the average period from the onset 
of the discharge to the beginning of the tests of cure 
was 9.6 weeks. Naturally, this refers only to "cured" 
or "probably cured" cases. The average period from the 
onset of the disease to the completion of the tests of 
cure was 18.3 weeks. This refers only to the "cured" 
cases. The average duration of the urethral discharge 
after commencement of treatment with M & B 693 was found 
to be 5.1 days. This figure is obtained from the records 
of "cured" and "probably cured" cases. Three long 
standing cases which had proved unresponsive to local 
treatment cleared up rapidly with M & B 693. One 
Uleron "failure" was likewise cured.
During treatment with the drug, three gonococcal 
complications supervened. There was one case of 
epididymitis, one of cystitis, and one of arthritis of 
the left wrist with toxic conjunctivitis.
/£ £  P R o q l e :/y\ o r  
A D J U V A N T  T f t B A  T/v1£n7~
Some comparison may be attempted of the results 
of treatment with or without local antiseptics. The 
following is a summary of the results obtained in 
group one (not irrigated) and group two (irrigated).
■ • G-roup ONE Group TWO
(Not irrigated) (Irrigated)
(Cases 1-50) (Cases 5 I7 IOO)
CURED  31    35
PROBABLY C U R E D   9 ..........  8
FAILED.................  4    4
RELAPSED............... 6   3
GONOCOCCAL
COMPLICATIONS 
AFTER STARTING
TREATMENT  1   2
These figures are suggestive, but alone they are 
not quite conclusive. They do indicate in favour of 
local antiseptic treatment, however, and especially 
is. this true of the "relapses”. A more striking 
contrast, hovever, is to be found in the average 
duration of urethral discharge in the two groups 
(after commencing chemotherapy). The figures are 
as follows
Non-irrigated group ........ 5.5 days.
Irrigated group.............  4.4 days.
There is concrete evidence here that M & B 693 
is more rapidly effective when the infection is 
being dealt with locally.
To x /c /t y ,
In 41 of a hundred male cases treated with M & B 
693 some toxic effects were apparent. Generally these 
were neither severe nor of long duration. Headache 
( often frontal and severe) was common, and nausea, 
giddiness, and vomiting were complained of by several 
patients. Four toxic rashes were seen, two macular 
(general), one erythematous (severe), and one urticari: 
Other signs or symptoms attributed to the action of 
the drug were abdominal pain, lack of energy, backache 
and "bumpy Heart”.
" 30-
CLINICRL.
MRT£RmU
TR£flTMErvr
TREATMENT WITH M & B 695. (50 cases of acute gonococcal
infections in the female). 
See Table IV.
M & B 693 was given to fifty cases of acute or 
sub-acute gonococcal infection in the female. On 
first attendance cervical and urethral smears were 
examined and, where necessary, a complement fixation 
test was done. All the patients v/ere found to have 
gonococci either in a urethral or cervical smear, 
or in both. The cases v/ere varied and typical, 
presenting the usual local and general complications 
of gonorrhoea in the female. Abdominal pain was 
encountered (5 cases) and in most cases there was 
cervical or urethral discharge, or both. Painful 
and frequent micturition was reported in half a 
dozen cases; erosion of the cervix was apparent 
in ten cases; arthritis of wrist, knee, ankle, and 
shoulder, urethral haemorrhage, vulvar inflammation, 
and vomiting were also present. There, were three 
cases of salpingitis (one severe), and one of 
Bartholin’s abscess. One patient had a secondary 
syphilitic rash.
Local treatment of the infected parts was given 
either daily or on alternate days, the discharge 
being removed with sodium bicarbonate solution.
Tbcchmhskje o p
/ /V/S~7V?/*97VO/V
In this series the normal course was 21 grammes 
(2 tablets three times daily for a v/eek). Where 
advisable this course was prolonged until 30 grammes 
had been administered. In seven cases it was found 
necessary to give a second course of treatment. Only 
two patients defaulted before the completion of the 
initial course.
The average interval between first attendance 
and the commencement of treatment with M &. B 693 was
31.3 days. It should he pointed out that, as in the 
group of male patients treated with M & B 693, this 
average is increased considerably by the inclusion 
of several cases which had proved resistant to other 
methods of treatment. If ten such cases are left out 
of the count the average is lowered to 9.5 days. This 
is a fairer picture of the general procedure in this 
group.
R e s u l t s .
Twenty-six cases passed all T.O.G. and were 
discharged as cured (52 per cent.). We may add to 
this twelve more cases classed as ” probably 
cured”. These were cases who defaulted, or who 
for some reason were not subjected to thorough 
tests. In this series there was little early 
default, and a certain amount of confidence can 
be felt even in these somewhat dubious cases.
Adding these probable successes to the "cures" we 
obtain a maximum success rate of 76 % m Only two 
cases relapsed after treatment: ten patients .
responded erratically or not at all —  they are 
regarded as M & B failures.
J^JSCussiorV.
Further classification of these results is 
necessary in view of the fact that more than the 
normal course of 21 grammes was frequently given, 
and in one or two cases the dosage was less than 
21 grammes. One case (No.F 32) was cured after 
26 tablets. Two patients defaulted after having 
30 and 36 tablets respectively. In one instance 
the patient was a gonorrhoeal contact with a slight 
infection which cleared rapidly; the other 
experienced a rapid recovery but encountered nausea 
due to the drug. These are both classed as probable 
cures (their protocols may be examined on Table IV
Patients F 2 and F 48). Of those who received 42 tablets 
only, 13 were cured, 8 probably cured, 2 relapsed, and 
3 failed to respond and were treated by other methods. 
Fourteen patients had a course of 60 tablets, eight 
being cured and two probably cured. Four still 
failed to respond. Finally seven patients were 
given a second course of the drug ; four were cured, 
and three remained unresponsive.
During treatment a clinical and pathological 
examination was carried out as frequently as possible 
(in many cases daily) and the record of these 
examinations will be found in Table IV. In the 38 
cases which responded favourably, gonococci were absent 
after about three days treatment. Where discharges did 
cease, they ceased rapidly. Urethral discharges in 
33 cases cleared up in an average time of 3.4 days. 
Cervical discharges were more persistent, but in 18 
cases they ceased in 5.7 days.
Tests of cure have already been described. The 
average period between the first attendance and final 
T.O.C. was 30.8 weeks.
It is noticeable in the protocols of these cases 
that where M & B 693 succeeds it does so with 
remarkable dispatch. On the other hand, it seems that 
where it is unsuccessful its failure is not to be 
eradicated merely by persistence. In this connection, 
it must be remembered that consideration for the 
comfort of the patient often precludes a too-persistent 
application of the drug.
In the present group of cases M & B 693 proved 
a pov^erful therapeutic agent for gonorrhoea in the 
female. Local foci of infection responded well to 
antiseptic measures, and indeed seemed more amenable 
to treatment whilst the blood was impregnated with 
the drug.
7ox/c  
XEfitTfONS.
It has been the experience or some clinicians that 
women are treated with difficulty by sulphanilamide 
chemotherapy on account of their unwillingness to 
suffer the attendant discomforts which are often 
to be sustained during treatment. Some of the cases 
here described complained of headache, others of 
nausea, vomiting, giddiness, debility, ’’rigor”, and 
dyspnoea. An erythematous and an urticarial rash 
were seen, together with seven other rashes of 
varying severity. In all, 29 patients, or 58 % of 
the cases treated, suffered in some fashion from 
secondary effects of M & B 693. There was no reason 
to suppose, however, that the great majority aid not 
persevere with the recommended dosage. It is 
probable that very frequent examination and reassura: 
wherever.possible, will overcome this difficulty.
SUMMARY OF RESULTS OBTAINED WITH ULERON, ALBUCID, 
AND M & B 695 IN THE TREATMENT'OF ACUTE GONORRHOEA 
OF THE MALE.
ULERON ALBUCID M & B 695
(100 cases) (50 cases) (lOO cases)
CORED...........
PROBABLY CORED--.
59 %' 
15
•-74 %
o>
1 
o
•60 %
66 % 
17 %
RELAPSED........
FAILED..........
9 % 
17 %
•26 %
20 % 
20 %
.40 %
9 %'
>
8 %
TOXIC EFFECTS 
RESOLTING FROM . . 
OSE OF DROG
9 % 8 % 41 %
DROG RASHES .... 2 % 1 % 4 %
■83 %
17 %
in above)
With reference to the toxicity of the respective 
drugs, it should be pointed out again that a special 
technique of administration was adopted in the case of 
ULERON with a view to diminishing secondary reactions. 
Whether this should be done in the case of M & B 693 is 
debatable. The high percentage of toxic reactions 
seems to favour such a course. On the other hand, the 
intensive treatment seems justified by its therapeutic 
effect, and the toxic conditions encountered were not 
generally so severe as to prove an obstacle to 
treatment.
SUMMARY OF RESULTS OBTAINED WITH M & B 693 IN THE
TREATMENT OF ACUTE 'GONORRHOEA OP THE FEMALE.
M & B 693 
(50 cases)
C U R E D    52 %
PROBABLY CURED  24 % .
RELAPSED............  4 %
FAILED  20 %
TOXIC EFFECTS  58 %
DRUG- RASHES.........  IQ %
(Included in 
above).
76 %
•24. %
These results compare quite favourahly with those 
'obtained in the treatment of male cases with M & B 693. 
The percentage of patients suffering from toxic effects, 
especially from skin eruptions due to the action of the 
drug, is much higher.
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Abbreviations used in the TABLES.
GL = Urine clear.
Ts = Urine threads.
Sps = Urine specks.
H = Urine hazy.
Oc = Occasional, (e.g. Oc Ts = Occasional urine threads) 
F = Few.
G.l.= Acute gonorrhoea.
D = Discharge.
CD = Cervical discharge.
UD = Urethral discharge.
PC = Pus cells.
EG = Epithelial cells.
Os = Organisms (Not including gonococci)
GC = Gonococci.
C = Cervix
U = Urethra.
T.O.C. = "Routine tests of cure in a gonorrhoeal case"
When referring to a "Discharge" ++ = profuse
+ = moderate
± = slight
- = none
When referring to "Organisms or Cells" ++ = very many
+ = many 
± = few 
= none
N.V.D. = Not Venereal Disease (Non-venereal)
N.A.D. = No apparent disease.
"ULERON" / ftaL tz 1
PLEASE TURN THIS MARGINAL 
INDEX OUT WHEN READING 
TABLE Z . .
W HEM NOT CONSULTfN Gj T~/)BLE J_ 
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. unition.
Hu sb and ha s GC.
an GC GC
GO (?) GC GO
5 7 4
YSS YES YES
* * *
: OD .: • UD : GD 5 UD ; 
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GO ±  C ? ) GG “ GG d-
3 5 21
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d~ — ■
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GG-4-
jGCL
7
YSS
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No
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4- -f~ —
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’’Probably CURED”
Female patient's serial number.
Chief symptoms on 1st attendance 
Chief signs on 1st attendance.
Pathological tests on 1st attendance.
Cervical smear (C) 
Urethral smear (U)
C.F.T. for G.G. 
_______________Culture.__________________
Interval (in days) from 1st attendance 
to day on which M.& B. 693 commenced.
Whether or not local treatment of the 
infected parts was also given.
Type of local treatment.Either daily or on
alternate d a y s . _______
Cervical & urethral picture 
after M.& B. 693 tablets
12
18
24
30
36
42
48
54
60
Cervical smear (C) & Urethral smear (U) 
after M.& B. 693 tablets 6 (0)
UJ
12 (0 J
-UU
IB (C)
HU
24. (C)
 013
30 (C)
36 {G)
w
42 (C)
-00
48 [G)
 Ox
54 (C
XII3
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 01
Whether or not a 2nd Course of tablets 
was given.
Notes regarding response to M.4: B.693 
Symptoms etc due to the drug.
Whether or not complete 'Tests of Cure' 
(T.O.C.) were carried out.
Number of weeks which elapsed between 
1st attendance & Pinal test of T.O.C.
"CURED”
"Probably CURED” 
"Relapse FAILURE” 
"Complete FAILURE”
